Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

423 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Harbeck N, Nimmrich I, Hartmann A, Ross JS, Cufer T, Grützmann R, Kristiansen G, Paradiso A, Hartmann O, Margossian A, Martens J, Schwope I, Lukas A, Müller V, Milde-Langosch K, Nährig J, Foekens J, Maier S, Schmitt M, Lesche R. Harbeck N, et al. Among authors: hartmann a, hartmann o. J Clin Oncol. 2008 Nov 1;26(31):5036-42. doi: 10.1200/JCO.2007.14.1697. Epub 2008 Aug 18. J Clin Oncol. 2008. PMID: 18711169
DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME, Schwope I, Bolt-de Vries J, Harbeck N, Koenig T, Hartmann O, Kluth A, Dietrich D, Magdolen V, Portengen H, Look MP, Klijn JG, Lesche R, Schmitt M, Maier S, Foekens JA, Martens JW. Nimmrich I, et al. Among authors: hartmann o. Breast Cancer Res Treat. 2008 Oct;111(3):429-37. doi: 10.1007/s10549-007-9800-8. Epub 2007 Oct 28. Breast Cancer Res Treat. 2008. PMID: 17965955
DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.
Hartmann O, Spyratos F, Harbeck N, Dietrich D, Fassbender A, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Lerebours F, Welzel K, Maier S, Plum A, Niemann S, Foekens JA, Lesche R, Martens JW. Hartmann O, et al. Clin Cancer Res. 2009 Jan 1;15(1):315-23. doi: 10.1158/1078-0432.CCR-08-0166. Clin Cancer Res. 2009. PMID: 19118060 Clinical Trial.
Stable Peptide of the Endogenous Opioid Enkephalin Precursor and Breast Cancer Risk.
Melander O, Orho-Melander M, Manjer J, Svensson T, Almgren P, Nilsson PM, Engström G, Hedblad B, Borgquist S, Hartmann O, Struck J, Bergmann A, Belting M. Melander O, et al. Among authors: hartmann o. J Clin Oncol. 2015 Aug 20;33(24):2632-8. doi: 10.1200/JCO.2014.59.7682. Epub 2015 Jul 13. J Clin Oncol. 2015. PMID: 26169618
Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment.
Buerger K, Uspenskaya O, Hartmann O, Hansson O, Minthon L, Blennow K, Moeller HJ, Teipel SJ, Ernst A, Bergmann A, Hampel H. Buerger K, et al. Among authors: hartmann o. J Clin Psychiatry. 2011 Apr;72(4):556-63. doi: 10.4088/JCP.09m05872oli. Epub 2010 Nov 2. J Clin Psychiatry. 2011. PMID: 21208578
Activity of the adrenomedullin system to personalise post-discharge diuretic treatment in acute heart failure.
Kozhuharov N, Ng L, Wussler D, Strebel I, Sabti Z, Hartmann O, Eltayeb M, Squire I, Nowak A, Rieger M, Martin J, Michou E, Stefanelli S, Puelacher C, Shrestha S, Belkin M, Zimmermann T, Lopez-Ayala P, Struck J, Bergmann A, Mebazaa A, Blet A, Gualandro DM, Breidthardt T, Mueller C. Kozhuharov N, et al. Among authors: hartmann o. Clin Res Cardiol. 2022 Jun;111(6):627-637. doi: 10.1007/s00392-021-01909-9. Epub 2021 Jul 23. Clin Res Cardiol. 2022. PMID: 34302189 Free PMC article.
423 results